Tags: Drug.

Fosaprepitant (Emend for Injection (US) Ivemend (EU)) is an antiemetic drug administered intravenously. It is a prodrug of aprepitant.Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25 2008 and by the European Medicines Agency (EMA) on January 11 of the same year.

Fosaprepitant.svg
ATC prefix
A04
ATC suffix
AD12
CAS number
172673-20-0
CAS supplemental
(dimeglumine)
DrugBank
DB06717
FDA UNII code
6L8OF9XRDC
IUPAC name
[3-[(2R3S)-2-[(1R)-1-[35-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl-5-oxo- 2H-124-triazol-1-yl]phosphonic acid
PubChem
219090

Loading...

This page contains content from the copyrighted Wikipedia article "Fosaprepitant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.